← 返回

脱缰的杀手:提升基于 NK 细胞的肿瘤治疗效果的免疫治疗策略

英文原题:Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment.

查看英文原题

Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment.

PubMed 2022/05/16(内容时间) Int Rev Cell Mol Biol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞是先天淋巴细胞,既可直接杀伤癌细胞控制肿瘤进展,也可调节其他免疫细胞,协同组织抗肿瘤应答。然而,尽管NK细胞潜力巨大,近年之前多种NK细胞免疫治疗策略的临床结果总体较有限。这可能是因为调节NK活化的内在机制复杂,且肿瘤细胞已发展出多种逃逸NK细胞介导细胞毒作用的机制。当前增强NK细胞长期功能的策略主要是调节其活化和抑制相关分子;最新数据似乎支持联合靶向NK调控多个方面。本综述总结当前用于利用这一强效且复杂免疫细胞的多种策略,包括工程化NK细胞、CAR-NK及NK细胞免疫衔接器。

展开英文摘要原文

Natural killer (NK) cells are innate lymphocytes that control tumor progression by not only directly killing cancer cells, but also by regulating other immune cells, helping to orchestrate a coordinated anti-tumor response.

However, despite the tremendous potential that this cell type has, the clinical results obtained from diverse NK cell-based immunotherapeutic strategies have been, until recent years, rather modest. The intrinsic regulatory mechanisms that are involved in the control of their activation as well as the multiple mechanisms that tumor cells have developed to escape NK cell-mediated cytotoxicity likely account for the unsatisfactory clinical outcomes.

The current approaches to improve long-term NK cell function are centered on modulating different molecules involved in both the activation and inhibition of NK cells, and the latest data seems to advocate for combining strategies that target multiple aspects of NK cell regulation. In this review, we summarize the different strategies (such as engineered NK cells, CAR-NK, NK cell immune engagers) that are currently being used to take advantage of this potent and complex immune cell.

论文信息

作者
Dunai C、Ames E、Ochoa MC、Fernandez-Sendin M、Melero I、Simonetta F、Baker J、Alvarez M
第一作者单位
Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, United Kingdom.United Kingdom
通讯作者单位
Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Electronic address: malvarezr@unav.es.Spain
文献类型
综述 · 非美国政府资助研究
期刊
International review of cell and molecular biology2022
原文标识
PubMed 35798507 · DOI 10.1016/bs.ircmb.2022.04.001